Please use this identifier to cite or link to this item: https://doi.org/10.1007/s12975-013-0281-2
Title: Therapeutic Antibodies in Stroke
Authors: Yu, C.Y 
Ng, G
Liao, P 
Keywords: adalimumab
alpha amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid
CD18 antibody
CD18 antigen
endothelial leukocyte adhesion molecule 1
endothelial leukocyte adhesion molecule 1 antibody
enlimomab
Fas ligand
glutamate receptor antagonist
infliximab
intercellular adhesion molecule 1
intercellular adhesion molecule 1 antibody
interleukin 8
interleukin 8 antibody
L selectin
l selectin antibody
monoclonal antibody
myelin associated glycoprotein
n methyl dextro aspartic acid receptor
neutralizing antibody
Nogo 66 receptor
Nogo A antibody
oligodendrocyte myelin glycoprotein
PADGEM protein
protein antibody
protein Nogo A
recombinant plasminogen activator
tissue plasminogen activator
unclassified drug
active immunization
acute kidney failure
anaphylaxis
aseptic meningitis
blood brain barrier
brain damage
brain edema
brain hemorrhage
brain ischemia
cell infiltration
cerebrovascular accident
Crohn disease
deterioration
diarrhea
dyspnea
fatigue
fever
headache
heart arrest
heart infarction
heart palpitation
hoarseness
human
immunotherapy
leukocyte function
lung edema
lung embolism
malaise
meningitis
middle cerebral artery occlusion
nausea
nerve cell plasticity
passive immunization
pneumonia
priority journal
protein subunit
review
rheumatoid arthritis
side effect
spinal cord injury
stroke related deterioration
tissue injury
treatment failure
vein thrombosis
Antibody
Immunotherapy
Stroke
Animals
Antibodies
Biomedical Research
Cell Adhesion Molecules
Cytokines
Humans
Immunologic Factors
Immunotherapy
Myelin Proteins
Neuroprotective Agents
Stroke
Issue Date: 2013
Citation: Yu, C.Y, Ng, G, Liao, P (2013). Therapeutic Antibodies in Stroke. Translational Stroke Research 4 (5) : 477-483. ScholarBank@NUS Repository. https://doi.org/10.1007/s12975-013-0281-2
Rights: Attribution 4.0 International
Abstract: Immunotherapy represents an active area of biomedical research to treat cancer, autoimmune diseases, and neurodegenerative disorders. In stroke, recanalization therapy is effective in reducing brain tissue damage after acute ischemic stroke. However, the narrow time window restricts its application for the majority of stroke patients. There is an urgent need to develop adjuvant therapies such as immunotherapy, stem cell replacement, and neuroprotective drugs. A number of molecules have been targeted for immunotherapy in stroke management, including myelin-associated proteins and their receptors, N-methyl-d-aspartic acid receptors, cytokines, and cell adhesion molecules. Both active vaccination and passive antibodies were tested in animal models of acute ischemic stroke. However, the mechanisms underlying the efficacy of immunotherapy are different for each target protein. Blocking myelin-associated proteins may enhance neuroplasticity, whereas blocking adhesion molecules may yield neuroprotection by suppressing the immune response after stroke. Although results from animal studies are encouraging, clinical trials using therapeutic antibodies failed to improve stroke outcome due to severe side effects. It remains a challenge to generate specific therapeutic antibodies with minimal side effects on other organs and systems. © 2013 The Author(s).
Source Title: Translational Stroke Research
URI: https://scholarbank.nus.edu.sg/handle/10635/181806
ISSN: 18684483
DOI: 10.1007/s12975-013-0281-2
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s12975-013-0281-2.pdf173.08 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons